Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma
Source: OncLive, July 2024
Adjuvant nivolumab (Opdivo) in combination with ipilimumab (Yervoy) significantly improved 3-year distant metastasis–free survival (DMFS) rates compared with historical controls in patients with high-risk uveal melanoma, according to findings from the phase 2 HCRN MEL17-309 trial (NCT03528408) presented at the 2024 ASCO Annual Meeting.
At a median follow-up of 36.8 months, the adjusted 3-year DMFS rate with nivolumab plus ipilimumab was 70.4% (95% CI, 56%-85%) vs 43.4% (95% CI, 30%-56%) with external controls (relative risk, 0.52; 95% CI, 0.31-0.88; 2-sided P = .018). The median DMFS with nivolumab plus ipilimumab was not reached (NR; 95% CI, 44.8 months–NR) vs 32.3 months (95% CI, 29.4-44.8) with controls.
“Metastatic uveal melanoma has a poor prognosis, and the few approved treatment options are restricted to specific populations,” lead study author Suthee Rapisuwon, MD, said in the presentation. Rapisuwon is a medical oncologist, medical geneticist, and hematologist at MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center in Washington, DC.